Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Neuropsychobiology|July 3, 2009
Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorderJay D Amsterdam, David Williams, David Michelson, et al.
Psychiatry Research|December 9, 2009
Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetineFrederick Reimherr, Jay Amsterdam, David Dunner, et al.
Cephalalgia : an International Journal of Headache|June 9, 2016
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraineTiffini Voss, Richard B Lipton, David W Dodick, et al.
Neurology|August 10, 2014
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine preventionTony W Ho, Kathryn M Connor, Ying Zhang, et al.
JAMA Neurology|November 3, 2015
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedRobert A Hauser, Fabrizio Stocchi, Olivier Rascol, et al.
Biological Psychiatry|January 28, 2003
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesDavid Michelson, Lenard Adler, Thomas Spencer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 11, 2002
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trialChristopher J Kratochvil, John H Heiligenstein, Ralf Dittmann, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|June 15, 2004
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorderLouis S Matza, Anne M Rentz, Kristina Secnik, et al.
The International Journal of Neuropsychopharmacology|June 6, 2017
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive DisorderKathryn M Connor, Paulette Ceesay, Jill Hutzelmann, et al.
The International Journal of Neuropsychopharmacology|March 17, 2016
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary InsomniaKathryn M Connor, Erin Mahoney, Saheeda Jackson, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Neuropsychobiology|July 3, 2009
Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorderJay D Amsterdam, David Williams, David Michelson, et al.
Psychiatry Research|December 9, 2009
Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetineFrederick Reimherr, Jay Amsterdam, David Dunner, et al.
Cephalalgia : an International Journal of Headache|June 9, 2016
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraineTiffini Voss, Richard B Lipton, David W Dodick, et al.
Neurology|August 10, 2014
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine preventionTony W Ho, Kathryn M Connor, Ying Zhang, et al.
JAMA Neurology|November 3, 2015
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons LearnedRobert A Hauser, Fabrizio Stocchi, Olivier Rascol, et al.
Biological Psychiatry|January 28, 2003
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesDavid Michelson, Lenard Adler, Thomas Spencer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 11, 2002
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trialChristopher J Kratochvil, John H Heiligenstein, Ralf Dittmann, et al.
Journal of Developmental and Behavioral Pediatrics : JDBP|June 15, 2004
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorderLouis S Matza, Anne M Rentz, Kristina Secnik, et al.
The International Journal of Neuropsychopharmacology|June 6, 2017
Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive DisorderKathryn M Connor, Paulette Ceesay, Jill Hutzelmann, et al.
The International Journal of Neuropsychopharmacology|March 17, 2016
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary InsomniaKathryn M Connor, Erin Mahoney, Saheeda Jackson, et al.
Pageof 9